Germany - medicaments

Description

The purpose of this announcement is to conclude agreements on the active substance "leuprorelin acetate (ATC code: L02AE02)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure but a publication of the invitation to conclude/join/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The contract shall be concluded or accession shall take place by sending the required self-declarations and annexes as well as the contract or contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract shall be 1.5.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 5.4.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for receipt of accessions is 5.3.2021. In any case, the contracts will expire on 30.4.2021. The purpose of this announcement is to conclude agreements on the active substance "budesonide and formoterol (ATC code: R03AK07)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "agomelatine (ATC code: N06AX22)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Albendazole (ATC code: P02CA03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "amlodipine and candesartan (ATC code: C09DB07)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Book V (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Brivudin (ATC code: J05AB15)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts will expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "iron carboxymaltose (ATC code: B03AC)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Fluticasone and Salmeterol, pharmaceutical form: DOS, IHP (ATC code: R03AK06)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Macrogol, nur Arzneimittel (ATC-Code: A06AD65)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Midazolam (ATC code: N05CD08)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts will expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Prasugrel (ATC code: B01AC22)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch), Fifth Book (SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts will expire on 30.04.2021. The purpose of this announcement is to conclude agreements on the active substance "Triamcinolone Depot (ATC code: H02AB08)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Security Code (Sozialgesetzbuch, Fünftes Buch, SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. The corresponding information under IV.1.1 is only due to the classification of this form. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The information in point II.2.5) is due to the nomenclature of this publication form. The conclusion of the contract or an accession takes place by sending the required self-declarations and attachments as well as the contract or the contracts by e-mail (openhouse.rabattvertrag2019-1@kbs.de) to the KBS. The earliest commencement date of the contract is 01.05.2019, provided that the contract and the required declarations or proofs have been received by the KBS by e-mail (openhouse.rabattvertrag2019-1@kbs.de) by 05.04.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.03.2021. In any case, the contracts expire on 30.04.2021.

Opportunity closing date

05 March 2021

Value of contract

£0-100k